Pramipexole in the treatment of advanced Parkinson's disease

European Journal of Neurology

Volumn 7, Issue SUPPL.1, 2000, Pages 21-25

  Moller J C ^a   Oertel, W H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Fluctuation; Hallucination; Phase III; Rest tremor

Indexed keywords

DOPAMINE 3 RECEPTOR; PLACEBO; PRAMIPEXOLE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCORING SYSTEM; TREMOR;

BENZOTHIAZOLES; CLINICAL TRIALS, PHASE III; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; THIAZOLES;

EID: 0034463371     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2000.0070s1021.x     Document Type: Conference Paper

References (10)

1. Pramipexole - A review of its use in the management of early and advanced Parkinson's disease
2. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
3. Cost eftiectiveness of pramipexole in Parkinson's disease in the US
4. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease
5. Clinical evaluation of pramipexole in advanced Parkinson's disease
6. Thc use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease
7. Efficacy, safety and tolerance of the nonergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double-blind, placebo-controlled, randomised, multicenter study
8. A nonergot dopamine agonist, pramipexole, in the therapy of advanced Parkinson's disease: Improvement of parkinsonian symptoms and treatment-associated complications. A review of three studies
9. Levodopa therapy of Parkinson's disease and associated long-term motor response complications
10. A double-blind, placebo-controlled, randomised, multi-center study of pramipexole in advanced Parkinson's disease